Mammalian genomes are more pervasively transcribed than previously expected [1] [2] [3] [4] . In addition to protein-coding genes, many types of noncoding RNAs (ncRNAs) are transcribed. Small regulatory ncRNAs, including small interfering RNAs (siRNAs), microRNAs (miRNAs) and Piwi-associated RNAs (piRNAs), function in genome defense and post-transcriptional regulation [5] [6] [7] . Near transcriptional start sites (TSS), divergent transcription by RNA polymerase can generate small ncRNAs ranging from 20 to 200 nucleotides, which have been variously named promoter-associated small RNAs (PASRs), transcriptioninitiation RNAs (tiRNAs) and TSS-associated RNAs (TSSa-RNAs) [8] [9] [10] [11] . However, it remains uncertain if these ncRNAs are functional or just represent byproducts of RNA polymerase infidelity 12, 13 . lncRNAs vary in length from several hundred bases to tens of kb; lncRNAs may be located in isolation from protein coding genes (long intergenic ncRNAs, or lincRNAs), or they may be interspersed nearby or within protein coding genes 14, 15 . Moreover, recent evidence suggest that active enhancer elements are also transcribed to produce ncRNAs 16, 17 .
A r t i c l e s
In this study, we create an ultrahighresolution tiling microarray to interrogate the transcriptional and chromatin landscape around the TSSs of 56 cell-cycle genes, including genes encoding all cyclins, cyclin-dependent kinases (CDKs) and cyclindependent kinase inhibitors (CDKIs) . We analyze a diverse collection of cells and tissue samples that interrogate distinct perturbations in cell-growth control. Our results reveal a map of extensive and choreographed noncoding transcription and identify a specific set of lncRNAs that function in the DNA damage response.
RESULTS

Extensive noncoding transcription near cell-cycle genes
To systematically discover functional ncRNAs in the regulatory region of human cell-cycle genes, we created a tiling array that interrogates at 5-nt resolution across 25 kb of the 9p21 locus (which encompasses CDKN2A (p16), p14ARF and CDKN2B (p15)), as well as from 10 kb upstream to 2 kb downstream of each TSS from 53 cell-cycle genes to include those that encode all known cyclins, CDKs and CDKIs ( Fig. 1a and Supplementary Table 1 ). These genes are also critical for fundamental biological processes such as senescence, self-renewal, DNA damage response and tumor formation [25] [26] [27] . Thus, we hybridized 54 pairs of polyadenylated RNAs from various human cells that were altered or perturbed through cell-cycle synchronization, DNA damage, differentiation stimuli, oncogenic stimuli or carcinogenesis (Supplementary Table 2) .
A peak calling algorithm searched for statistically significant signals above background and detected contiguous regions (peaks) of at least 50 bp. We then compiled statistically significant transcripts from all 108 channels of the 54 arrays, clustered all transcripts that overlapped by a minimum of 50 bases and identified clusters that were present in at least 10% of the samples. Averaging the signal intensity across all probes in a peak produced a quantitative estimate of transcript abundance. Despite possible 3′ bias caused by polyadenylated RNA selection, our procedure detected exon 1 transcription from the majority of cell-cycle coding genes (41 of the 56), showing that this custom tiling array can detect previously reported transcribed regions. In each individual sample, we detected an average of 73 of the 216 transcribed regions (with a range of 14-189 transcribed regions) that did not overlap with known exons of the 56 cell-cycle genes (Supplementary Fig. 1 ; an example of the CCNE1 locus in human fetal lung fibroblasts is shown in Fig. 1b) . Across all 108 samples, we identified a total of 216 discrete transcribed regions (Supplementary Table 3 ). The average transcript length was 234 nt (with a range of 50-1,494 nt). One hundred seventy one of the 216 (79%) previously unidentified transcribed regions were located 5′ of the TSS of the cell-cycle genes ('upstream'), 40 of the 216 (19%) were located within introns ('intronic'), and 5 of the 216 (2%) were located downstream of the 3′ end of CDKN2A.
Genes actively transcribed by RNA polymerase II are marked by trimethylation of histone H3 on lysine 4 (H3K4me3) and lysine 36 of histone H3 (H3K36me3), which reflect gene starts and bodies, respectively 28 . These chromatin marks can be used to identify noncoding transcription 14 . In a subset of our samples, we determined whether the 216 transcribed regions were similarly marked for active transcription by performing chromatin immunoprecipitation followed by hybridization to our custom tiling array (ChIP-chip). This analysis confirmed that the chromatin state at a majority of the newly A r t i c l e s defined transcripts was enriched in both H3K4me3 and H3K36me3 (Fig. 1b,c) . Using EpiGRAPH analysis to query our transcripts against approximately 900 published genomic attributes 29 , the 216 putative transcribed regions were enriched for H3K4me3 (P < 10 −9 ) and RNA polymerase II binding (P < 10 −7 ), providing further evidence that these genomic regions are actively transcribed.
To determine whether the 216 transcripts may encode previously unknown protein-coding exons or noncoding RNAs, we used a codon substitution frequency (CSF) analysis to assess for characteristic evolutionary signatures of protein-coding sequences across 21 sequenced mammalian genomes 30 . As expected, the transcribed regions that coincided with annotated exons had high CSF scores. However, over 86% of the new transcribed regions had CSF scores well below the threshold of known proteincoding genes and resembled known ncRNAs ( Fig. 1d and Supplementary Table 3) , suggesting that most of the new regions do not have protein-coding potential. BLAST analysis confirmed that the majority of the transcripts are not known protein-coding genes (Supplementary Table 3 ). Furthermore, none of the transcripts intersect known premiRNAs, C/D box small nucleolar RNAs, H/ACA box small nucleolar RNAs or small Cajal-body specific RNAs as annotated in the UCSC genome browser. Thereafter, we refered to these transcribed regions as long noncoding RNAs (lncRNAs). We aligned the RNA hybridization signals at all 56 proteincoding loci of all 108 samples relative to their TSS (Fig. 1e) . As expected, we found a peak immediately downstream of the TSS corresponding to exon 1 of the protein-coding gene. In addition, we found enrichment of noncoding transcription in the region 4-8 kb upstream of the TSS. Thus, unlike the previously described PASRs, tiny RNAs and TSSaRNAs, which are primarily located within 100 bp of the TSS, the majority of these ncRNAs are longer and are not clustered immediately around the TSS.
Expression patterns of ncRNAs suggest specific biological functions
Next, we examined the biological conditions that regulate expression of these ncRNAs in order to infer possible biological functions. We assembled a matrix of the expression changes of the 216 new transcribed regions across all 54 perturbations and hierarchically clustered the genes and samples ( Fig. 2a and Supplementary Table 4) . Of the 216 new transcribed regions, 92 (43%) had at least a twofold change in expression detected on the tiling array in at least one of the perturbations, suggesting that a large subset of the transcribed regions may have functional roles. The samples that had the most transcripts with at least twofold expression change were the embryonic stem cells (ESC) relative to day 152 fetal pancreas (40 of 216) and invasive ductal breast carcinomas relative to normal (as many as 35 of 216), suggesting that a subset of these lncRNAs may play a role in self-renewal and carcinogenesis (Fig. 2a) 31 . Notably, the lncRNA expression profile of MYC-RAS-IκBα cells clustered with that of ESCs (Fig. 2) , suggesting a shared lncRNA signature for embryonic and cancer stem cells. In contrast, the E2F3-RAS-IκBα transduced keratinocytes, which do not express the ESC-like mRNA gene expression program, had an inverse pattern of expression for the majority of lncRNAs. In addition, eight primary human invasive ductal breast carcinomas split into two different groups based on their lncRNA profiles: four of the cancers clustered with the ESCs and MYC-RAS-IκBα tumors, and the other four clustered with the E2F3-RAS-IκBα tumors, suggesting that these tumor models mimic the expression pattern of not only mRNAs but also these lncRNAs in bona fide human cancers. The 216 lncRNAs are divided into three main clusters based on their expression pattern across all samples (Fig. 2) . Notably, cluster 1 is composed of lncRNAs that are strongly induced in ESCs, keratinocytes with P63-knockdown and MYC-RAS-IκB tumors relative to differentiated cells and GFP-RAS-IκB tumors, which we interpret to be a 'stemness cluster' (Fig. 2b) . Notably, each cluster is composed of many of the ncRNAs from the same genomic locus, suggesting that multiple adjacent ncRNAs are either coordinately regulated in a shared response or are spliced together as exons of one transcript. High correlation of the dynamic expression patterns of these ncRNAs and different biological and cellular conditions suggest that these ncRNAs may be functional in the cell cycle, in self-renewal and in cancer.
A gene co-expression map infers trans regulatory mechanisms and biological functions
Multiple lncRNAs, including p15AS and the lncRNA upstream of CCND1, have been shown to regulate the transcription of the nearby coding gene. To determine whether gene-proximal lncRNAs are typically correlated with the expression of the nearest mRNA, we conducted whole-genome expression arrays on 17 samples that were also examined on our tiling array and calculated pairwise Pearson correlations between the expression patterns of each cellcycle promoter lncRNA versus every mRNA genome wide. Notably, there was no significant correlation or anti-correlation between most of the 216 lncRNAs and the nearby protein-coding mRNA, suggesting that most of the lncRNAs may not function in cis to activate or repress nearby mRNA expression (Fig. 3a) . Quantitative RT-PCR (qRT-PCR) analysis of lncRNAs and neighboring 5′ and 3′ mRNAs in 34 additional samples confirmed these findings (Supplementary Fig. 2 ). In contrast, we found that the median correlation between two ncRNAs of the same locus was positive, supporting our hypothesis that neighboring ncRNAs may be coordinately regulated, positively regulate each other and/or are exons of the same transcript (Fig. 3b) .
Given that expression of the 216 ncRNAs does not generally correlate with the mRNA in cis, we further explored the genes and pathways that they may regulate using a guilt-by-association approach 14 . For each lncRNA, we defined a co-expression gene set as the group of mRNAs that are positively or negatively correlated with that lncRNA across the 17 samples (R > 0.5 or R < 0.5, respectively) ( Supplementary  Fig. 3 ). We then constructed a gene module map 32 of the association of each lncRNA co-expression gene set versus the Gene Ontology Biological Processes gene set and performed biclustering to identify lncRNAs that are associated with distinct Gene Ontology terms (Fig. 3c) . This analysis revealed multiple sets of lncRNAs that are associated with biological processes including cell cycle, DNA recombination, ribonucleoprotein complex biogenesis and assembly, RNA splicing, and response to DNA damage. Thus, despite having limited correlation in expression to their neighboring protein-coding gene, the expression patterns of these lncRNAs are still strongly related to the cell cycle. We constructed a similar module map with curated gene sets of metabolic and signaling pathways as well as biological and clinical states from the Molecular Signatures Database (MSigDB c2 collection) 33 . This module map confirmed the enrichment for cell-cycle-related sets (for example, Cell Cycle Brentani or Cell Cycle KEGG). In addition, enriched modules included several poor prognosis breast cancer gene sets (BRCA estrogen receptor negative, BRCA prognosis negative and BRCA1 overexpressed up), DNAdamage-related gene sets (UVA/UVB), several oncogenic signatures A r t i c l e s (RAS, MYC) and stem-cell gene sets (hematopoietic stem cell, neural stem cell) ( Supplementary Fig. 4 ).
Validation of ncRNA expression in cell cycle, ESC differentiation, cancer and DNA damage response To validate these inferred functional associations, we designed qRT-PCR assays for 60 of the 216 new transcribed regions (53 upstream and 7 intronic) to obtain a more quantitative measure of these lncRNAs across different conditions. Expression in HeLa cells synchronized in cell cycle progression by double thymidine block showed that most of the IncRNA have periodic expression peaking at different phases of the cell cycle (Fig. 4a) 34 . Parallel analysis in primary human fibroblasts synchronized by serum stimulation confirmed the peak cell cycle phase of 74% of the lncRNAs with periodic expression pattern during the cell cycle (Fig. 4b) . Next, comparison of human ESCs and fetal pancreas at days 76 and 152 showed that a majority of these IncRNAs are regulated during differentiation (Fig. 4c) .
In addition, unsupervised clustering of lncRNA expression patterns in five metastatic breast cancers and five normal mammary tissues readily distinguished the five metastatic breast cancers from the normal mammary tissues (Fig. 4d) . Some of the lncRNAs, including upst:CCNL1:−2,767 and int:CDKN1A:+885 (Supplementary Table 3) , are repressed in the metastatic breast cancers relative to normal mammary tissues, whereas others, including upst:CDKN1A:−4,845, upst:CDKN2B:−2,817 and int:ARF:+4,517, are induced. Thus, the majority of these lncRNAs have periodic expression in the cell cycle and are differentially expressed in different states of cell differentiation and cancer progression. Our co-expression maps predicted associations of several IncRNAs with DNA damage response pathways ( Fig. 3c and Supplementary  Fig. 3) . In support of this finding, doxorubicin-treated human fetal lung fibroblasts showed at least twofold change in 12 of the 216 ncRNAs on the tiling array and by qRT-PCR (Fig. 2) . Notably, 2 of those 12 ncRNAs were located 5′ of the TSS of the canonical p53 target gene CDKN1A (upst:CDKN1A:−1,210 and upst:CDKN1A:−4,845), and, similar to the CDKN1A mRNA, were induced by doxorubicin (Fig. 5a) . In addition, a third lncRNA at the CDKN1A locus, upst:CDKN1A:−800, was also induced by doxorubicin but was not included in the 216 lncRNAs because it was only expressed in one of the 108 samples, the doxorubicin-treated fibroblasts. In order to confirm whether these lncRNAs may be responsive to DNA damage, we measured the expression changes of 60 lncRNAs predicted in the DNA damage pathway (as well as upst:CDKN1A:−800) by quantitative RT-PCR in human fetal lung fibroblasts treated with doxorubicin over a 24-h time course. Most of the lncRNAs were either markedly induced or repressed by doxorubicin, and all five of the tested lncRNAs surrounding the CDKN1A TSS were induced, including the three that were previously detected on the tiling array (Fig. 5b) . Notably, several IncRNAs upstream of CDKN1A are induced more rapidly and with substantially higher magnitude than CDKN1A upon DNA damage. Upst:CDKN1A:−4,845 is induced up to 40-fold upon DNA damage (Fig. 5c) . These variations in expression patterns within the same locus suggest that the lncRNAs in the CDKN1A locus may play distinct roles in the DNA damage response from the CDKN1A protein, p21.
PANDA: a long ncRNA involved in the DNA-damage response
To investigate the functional relevance of these lncRNAs at the CDKN1A locus, we selected upst:CDKN1A:−4,845, hereafter termed PANDA (P21 associated ncRNA DNA damage activated), for further analysis. PANDA is located approximately 5 kb upstream of the CDKN1A TSS, coincides with a cluster of previously annotated expressed sequence tags and is evolutionarily conserved (Supplementary Fig. 5 ). Although the PANDA locus intersects a computationally predicted pseudogene of LAP3, qRT-PCR showed that PANDA was specifically induced by DNA damage, whereas LAP3 expression did not significantly change, confirming that the change in expression detected by the tiling array was not caused by cross hybridization with LAP3 (Supplementary Fig. 6 ). Furthermore, the CSF score of PANDA, 9.3, indicated very low protein-coding potential compared to LAP3 (with a CSF range of 117-1,343 for its 13 exons). Rapid amplification of the 5′ and 3′ complementary DNA A r t i c l e s ends (RACE) and RNA blot analysis revealed a 1.5-kb transcript that is divergently transcribed from CDKN1A, antisense of the predicted LAP3 pseudogene (Fig. 5d and Supplementary Fig. 7) . Thus, PANDA is a 5′-capped and polyadenylated non-spliced lncRNA that is transcribed antisense to CDKN1A.
Because p53 is a positive regulator of CDKN1A during the DNA damage response, we asked whether p53 also regulates PANDA expression. ChIP-chip analysis confirmed the p53 binding site immediately upstream of the CDKN1A TSS (Fig. 5a) 35 . PANDA and CDKN1A are diametrically situated 2.5 kb from this intervening p53 binding site, which supports the possibility of p53 co-regulation. Indeed, siRNA-mediated knockdown of p53 before DNA damage inhibited the induction of PANDA by 70% 24 h after DNA damage ( Fig. 5e and Supplementary Fig. 8 ), which is similar to its effect on CDKN1A. In contrast, RNA interference of CDKN1A had no effect on PANDA expression, indicating that PANDA is not a linked transcript of CDKN1A nor is PANDA expression dependent on p21. PANDA level shows a trend of lower expression in human primary breast tumors harboring inactivating mutation in TP53 as determined by exon 2-11 DNA sequencing 36 ( Supplementary  Fig. 9a) . Further, complementation of p53-null H1299 lung carcinoma cells by wild-type p53-but not the loss-of-function p53 (p.Val272Cys) mutant-restored DNA damage-inducible expression of PANDA (Fig. 5f) . Notably, a gain-of-function p53 (p.Arg273His) mutant, observed in Li-Fraumeni syndrome 37 , abrogated the ability to induce CDKN1A but selectively preserved the ability to induce PANDA (Fig. 5f) . We also observed selective induction of PANDA without concordant CDKN1A expression in metastatic ductal carcinomas but not in normal breast tissue (Supplementary Fig. 9b ).
Next, we addressed whether PANDA affects the DNA damage response. We transduced human fetal fibroblasts (FL3) with custom siRNAs targeting PANDA and then applied doxorubicin for 24 h following the knockdown (Fig. 6a) . Global gene expression analysis showed that 224 genes were induced and 193 genes were repressed at least twofold by PANDA knockdown (Fig. 6b) . Genes induced by PANDA knockdown were significantly enriched for those involved in apoptosis, such as the Gene Ontology terms 'cell death' (P < 0.04) and 'apoptosis' (P < 0.03) (Fig. 6b) . qRT-PCR confirmed that PANDA depletion induced several genes encoding canonical activators of apoptosis, including APAF1, BIK, FAS and LRDD (Fig. 6c) . On the other hand, expression of neither CDKN1A itself nor TP53 was affected by PANDA depletion (Fig. 6d) , suggesting that PANDA is a P53 effector that acts independently of p21 CDKN1A .
DNA damage in human fibroblasts triggers p53-dependent G1 arrest but not apoptosis 38, 39 . Consistent with this finding, doxorubicin treatment in FL3 cells exposed to control siRNA had little to no apoptosis as measured by TUNEL. In contrast, PANDA knockdown resulted in fivefold to sevenfold increased TUNEL-positive cells (Fig. 6e,f) . Immunoblot analysis of PARP, a caspase substrate and marker of apoptosis, revealed PARP cleavage only in PANDA-depleted cells (Fig. 6g) . In contrast, six additional siRNAs targeting other transcripts within the CDKN1A promoter had no effect on apoptosis (data not shown; Supplementary Fig. 10 ). Thus, PANDA knockdown sensitized fibroblasts to DNA-damage-induced apoptosis. Altogether, these data suggest that in parallel with p53-mediated induction of CDKN1A for cell cycle arrest, p53-mediated induction of PANDA delimits apoptosis.
Core promoters of cell death genes downstream of p53 are distinguished from other p53 target genes by the binding site for the transcription factor NF-YA 40 , and we reasoned that PANDA may affect NF-YA function. RNA chromatography 41 using purified, in vitro transcribed PANDA RNA, but not a 1.2-kb LacZ mRNA fragment, specifically retrieved NF-YA from cellular lysates of human fibroblasts induced by DNA damage (Fig. 7a) . PANDA did not retrieve other chromatin modification complexes that can bind other lncRNAs, such as EZH2 or LSD1 (refs. 42,43) , or p21, illustrating the specificity of the interaction. Immunoprecipitation of NF-YA from doxorubicin-treated primary human lung fibroblasts specifically retrieved endogenous A r t i c l e s PANDA (Fig. 7b) . NF-YA is a nuclear transcription factor that activates the p53-responsive promoter of FAS upon DNA damage 40 . Depletion of PANDA substantially increased NF-YA occupancy at target genes, including CCNB1, FAS, BBC3 (also known as PUMA) and PMAIP1 (also known as NOXA) (Fig. 7c) . Moreover, concomitant knockdown of NF-YA and PANDA substantially attenuated induction of apoptotic genes and apoptosis as measured by TUNEL, indicating that NF-YA is required in part for cell death triggered by loss of PANDA (Fig. 7d,e) . Thus, PANDA binding to NF-YA may evict or prevent NF-YA binding to chromatin. These data suggest that DNA damage activates p53-mediated transcription at CDKN1A and PANDA that functions synergistically to mediate cell cycle arrest and survival. CDKN1A mRNA produces p21 to mediate arrest, whereas PANDA impedes NF-YA activation of apoptotic gene expression program (Fig. 8) .
DISCUSSION
Recent studies have revealed that a surprisingly large fraction of mammalian genomes is transcribed. In addition to small noncoding RNAs, long noncoding RNAs can be produced from gene promoters and enhancers, as well as stand-alone intergenic loci 14, 15, 17 . New approaches are needed that not only identify ncRNAs but also provide insight into their potential biological function. Using an ultrahigh-resolution tiling array, we interrogated the transcriptional landscape at cell-cycle promoters in 108 samples that represent diverse perturbations. The ability to interrogate numerous and diverse biological samples in a rapid and economical fashion is advantageous for at least two reasons. First, many of the noncoding transcripts are induced only in highly specific conditions and may have been missed if only a few conditions were surveyed. Of the 216 new noncoding transcribed regions we identified, on average, only 73 of these are transcribed in any one biological sample. Second, comparison of lncRNA profiles amongst these diverse samples highlighted unexpected similarities in cell cycle promoter states among distinct perturbations. For instance, we identified a similarity of promoter states among ESCs, tumors induced by MYC and epithelial progenitors depleted of the differentiation regulator p63. Likewise, authentic human tumors can be classified based on the similarity of their promoter states to those of cells with defined oncogenic perturbation.
Noncoding transcription through regulatory elements may affect gene activity in a variety of ways. The act of transcription may open compacted chromatin over regulatory sequences or compete with transcription factor binding (so called transcriptional interference). In addition, the ncRNA product may modulate neighboring gene expression in cis 21, 44 , affect distantly located genes in trans 22 A r t i c l e s serve as a target for regulation by small regulatory RNAs 45, 46 . Because these different mechanisms predict distinct relationships between levels of ncRNAs and cognate mRNAs, we compared ncRNA and mRNA expression profiles across our samples. We found that most promoter ncRNAs are neither positively nor negatively correlated in expression with their neighboring mRNA but are rather correlated in expression with genes located elsewhere in the genome. The genes co-expressed (and presumably co-regulated) with promoter ncRNAs function in specific biological pathways, including cell cycle, DNA damage response and stem cell differentiation, and have been associated with cancer prognosis. qRT-PCR analysis further validated that many of these ncRNAs are differentially expressed in the cell cycle and in human cancers, and are regulated in response to DNA damage or ESC differentiation. These findings suggest that cell-cycle ncRNAs may participate in gene regulation in trans. In addition, noncoding transcription of cellcycle promoters may be a form of regulatory anticipation or feedback to modulate the chromatin state of cell-cycle promoters. Our results suggest that the human genome is organized into genomic units that code for multiple transcripts that function in the same biological pathways (Fig. 8) . Forty nine of 56 cell-cycle proteincoding gene loci have at least one detected lncRNA and an average of four lncRNAs within 10 kb upstream and 2 kb downstream of the TSS. At the CDKN1A promoter, five lncRNAs, similar to the CDKN1A mRNA itself, are induced by DNA damage. One of these lncRNAs, which we named PANDA, is a non-spliced 1.5-kb ncRNA that is transcribed antisense to CDKN1A and is induced with faster kinetics than CDKN1A. Loss-of-function and complementation experiments show that PANDA induction during DNA damage is p53 dependent. In contrast, depletion of CDKN1A or depletion of PANDA had no effect on the other's response to DNA damage, indicating that their induction by p53 occurs in parallel. PANDA inhibits the expression of apoptotic genes by sequestering the transcription factor NF-YA from occupying target gene promoters. Whereas CDKN1A encodes a cell cycle inhibitor to mediate cell cycle arrest, PANDA promotes cell survival by impeding the apoptotic gene expression program. This linkage can be apparently exploited by tumors: the ability of the Li-Fraumeni gain-of-function P53 mutant p.Arg273His to selectively retain PANDA induction instead of CDKN1A in effect uncouples cell survival from cell cycle arrest, which was similarly observed in metastatic ductal carcinomas. Thus, lncRNAs like PANDA may provide new explanations for human cancer susceptibility.
Intriguingly, a recent study identified a distinct long intergenic noncoding RNA located 15 kb upstream of CDKN1A, named lincRNA-p21, that is induced by p53 and mediates p53-dependent gene repression 24 . Thus, the regulatory sequence upstream of CDKN1A drives the expression of multiple coding and noncoding transcripts that cooperate to regulate the DNA damage response (Fig. 8) . These findings provide a vivid example that shows the blurring boundary between 'genes' and 'regulatory sequences' 47 . 
A r t i c l e s
Our study provides an initial catalog of lncRNAs in cell-cycle promoters that may play diverse functions. At a minimum, promoter ncRNA expression provides a convenient means of tracking the chromatin state of promoters, which may be of use in cancer biology and regenerative medicine. Future studies are needed to pinpoint the functions of these and likely other ncRNAs emanating from regulatory sequences.
URLs. Genomica, http://genomica.weizmann.ac.il/.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. Tiling and microarray data are available at Gene Expression Omnibus (GSE28631). Sequence for human PANDA RNA has been deposited with GenBank under the accession number JF803844.
Note: Supplementary information is available on the Nature Genetics website.
ONLINE METHODS
Tiling array design and RNA hybridization. A custom tiling array (Roche NimbleGen) was designed at 5-bp resolution across 25 kb of the 9p21 region (which encompasses CDKN2A, P14ARF and CDKN2B), as well as from 10 kb upstream to 2 kb downstream of each TSS from 53 other cell-cycle genes, including those encoding cyclins, CDKs and CDKIs (Supplementary Table 1 ). In addition, the HOXA and HOXD loci were placed on the array as a control. Briefly, RNA was amplified (MessageAmp Kit, Ambion), reverse transcribed (RETROscript Kit, Ambion), labeled and hybridized according to the standard NimbleGen protocol.
Peak calling. Robust multichip average normalized single channel data from each array were subjected to peak calling using the NimbleScan program (Roche NimbleGen) with a window size of 50. Peaks with a peak score greater than ten were considered significant transcriptional units. Peak calls from all 55 array samples were clustered using Galaxy 2, 48 , and only transcripts present in a minimum of 10% of the samples were considered for further analysis. Transcripts were annotated as follows: 'genomic location (upstream of TSS of cell-cycle protein-coding gene, upst; exon of cell-cycle protein-coding gene, exon; intron of cell-cycle protein-coding gene, int; downstream of cell-cycle protein coding gene, dst)'; 'gene symbol of nearest mRNA'; 'distance from TSS' .
Measuring protein-coding potential. To assess the coding potential of the new transcribed regions, we evaluated the evolutionary signatures in their alignments with orthologous regions in 20 other sequenced placental mammalian genomes using the codon substitution frequencies (CSF) method 30, 49, 50 , which has also been applied to assess new transcribed regions in mouse 14 . CSF produces a score for any region in the genome considering all codon substitutions observed within its alignment, based on the relative frequency of similar substitutions in known coding and noncoding regions. Briefly, CSF performs a statistical comparison between two empirical codon models 51 , one estimated from alignments of known coding regions and the other based on noncoding regions, and reports a likelihood ratio that quantifies whether the protein-coding model is a better explanation while controlling for the overall level of sequence conservation 30 .
Module map analysis. We generated a module map of the ncRNAs versus the protein-coding genes by computing the Pearson correlations for all pairwise combinations based on expression across 17 different samples. This map was clustered and visualized using the program Genomica (see URLs). For each ncRNA, we then defined gene sets of the protein-coding genes that had a Pearson correlation that was greater than or less than 0.5 with that ncRNA. To determine functional associations, we then generated a module map of these ncRNA gene sets with Gene Ontology Biological Processes gene sets (Fig. 3c) and with curated gene sets of metabolic and signaling pathways and biological and clinical states from the Molecular Signatures Database (MSigDB c2 collection) ( Supplementary Fig. 4 ) 33 . The P value of enrichment was determined by the hypergeometric distribution, and a false discovery rate (FDR) calculation was used to account for multiple hypothesis testing (P < 0.05, FDR < 0.05).
Tissue samples and cells. Informed consent was obtained for tissue donation, and we obtained approval from institutional review boards of Stanford University, Johns Hopkins University and Netherlands Cancer Institute. Human primary breast tumors from The Netherlands Cancer Institute 52 and normal breast tissues and metastatic breast tumors from the Johns Hopkins University Rapid Autopsy Program are as described 23 . Human fetal pancreata were obtained from the Birth Defects Research Laboratory, University of Washington. Staged fetal pancreata were processed within 24 h of receipt, minced, washed and processed for RNA isolation using standard methods. Human fetal lung fibroblasts FL3 (Coriell AG04393) or foreskin fibroblasts (ATCC CRL2091) were cultured in 10% FBS (Hyclone) and 1% penicillinstreptomycin (Gibco) at 37 °C in 5% CO2.
